Testing a New Bowel Inflammation Treatment for Crohn's and Colitis

Plain-English translation of NCT07216014 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

What is this trial?

This study is testing a medication called an interleukin-23 monoclonal antibody to see how well it works for people with moderate to severe Crohn's disease or ulcerative colitis. Researchers will track how the medication affects your symptoms, inflammation, and overall health over about a year. They will also carefully monitor for any side effects to make sure the treatment is safe.

Crohn's disease and ulcerative colitis are serious conditions that cause chronic inflammation in the digestive system. This medication is designed to reduce that inflammation by targeting a specific protein involved in the disease process, and this study will help doctors understand whether it is truly effective and safe for patients.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you have been diagnosed with moderate to severe Crohn's disease or ulcerative colitis according to Chinese medical guidelines
you are willing and able to receive the medication by injection (either under the skin or into a vein) on a regular schedule
you understand the purpose of the study, the medication's effects, and possible side effects, and you agree to participate
if you are a woman who can become pregnant, you have a negative pregnancy test and agree to use contraception during the study

You likely don't qualify if…

you have other types of bowel inflammation, such as infections, radiation damage, or NSAID-related inflammation
you are unable to receive regular injections or have had extensive bowel surgery (such as removal of part or all of your colon)
you have severe liver or kidney disease, active infections, or tuberculosis
you have a history of cancer, lymphoma, heart problems, or certain neurological conditions
you have had severe or recurrent opportunistic infections in the past

What participation looks like

You will receive the new medication as an injection on a regular schedule while your doctor monitors your condition. Over about one year, you will have follow-up visits at weeks 0, 4, 8, 16, 24, 48, and 54 where you will undergo blood tests, provide stool samples, and possibly have bowel imaging or a scope examination. You will also complete questionnaires about your symptoms and any side effects, and the study team will collect tissue samples if imaging tests are needed.

Testing a New Bowel Inflammation Treatment for Crohn's and Colitis

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)